Kornimate/medical-research-clean huggingface dataset:
theta burst stimulation in young adults with depression

Conditions: Depression

Summary: for the proposed 2-year study, the investigators will conduct a within-subject, counterbalanced investigation using functional magnetic resonance imaging (fmri) and transcranial magnetic stimulation (tms) to examine the acute effects of theta-burst stimulation (tbs) on function in dorsomedial prefrontal cortex (dmpfc) in 35 young adults with depression (18-25 years, 50% female).

each participant will undergo 3 sessions of tms, one each of continuous and intermittent tbs--with the goal of decreasing or increasing dmpfc responding, respectively--and one of sham tbs. session order will be counterbalanced, with a double-blind approach to condition. brain function, behavior, and mood will be assessed before and after each tbs session. broadly, the investigators predict that inhibitory tbs to the dmpfc will enhance neural, behavioral, and subjective aspects of reward function by reducing dmpfc function and dmpfc connectivity with the ventral striatum (vs).

Eligibility criteria:
inclusion criteria: • dsm-5 diagnosis of major depressive disorder, persistent depressive disorder (dysthymia), other specified depressive disorder, or other unspecified depressive disorder exclusion criteria: * bipolar disorder, substance dependence, or lifetime history of psychosis * neurological disorder (e.g., seizure disorder) * pregnant * mri contradictions: claustrophobia, permanent orthodontic devices, metal implants or other forms of metal in the body that cannot be removed
aimmune - artificial intelligence algorithm for identification of immunogenic neoepitopes of cancer to predict and boost patient's response to immunotherapies.

Conditions: Non Small Cell Lung Cancer; Neoepitopes; Neoantigens; Immunotherapy; Next Generation Sequencing (NGS); Personalized Neoantigen Cancer Vaccine

Summary: the goal of the project is to develop and validate a.i.mmune technology. it performs complex analyses of patients' tumor and immune system state using data derived from next-generation sequencing of tumor and healthy tissue to identify cancer neoantigens, which are likely to elicit an immune response. a key challenge to be solved using the technology is to predict for each patient which neoepitopes are not only likely to bind to hla or be presented on the tumor cell surface, but also will be recognized by the t-cell receptor and create the immunogenic response. the presence of such epitopes is required for immunotherapy by immune checkpoint inhibition to have an effect on the disease. knowledge of those epitopes enables therapeutic strategies to boost the immune response by designing personalized cancer vaccines and adoptive cell therapies. the samples and data collected in this clinical study will be used for clinical validation of a.i.mmune technology. for all patients treated with immunotherapy (using anti-pd1 / anti-pdl1 and / or anti-ctla-4 antibodies) peripheral blood samples (pbmc) and biopsy (ffpe) collection will be performed before treatment. samples will be sequenced by next-generation sequencing platform. in parallel, the investigators will also collect samples of stool (one sample before the start of immunotherapy) and follow-up information of responses to treatment.


Eligibility criteria:
inclusion criteria: * men or women ≥18 years of age. * patients with non-small cell lung cancer. * patients with informed consent to participate in the study. * patients receiving routine treatment (immunotherapy using anti-pd1 / anti-pdl1 and / or anti ctla4 antibodies), financed by the polish national health fund (nfz). * the applied immunotherapy should be the first or second line of treatment. exclusion criteria: * patients who are unable to understand, read and / or sign informed consent. * patients who can not collect stools. * patients with fecal transplant. * the applied immunotherapy is not the first or second line of treatment.

Keywords: cancer non small cell lung cancer neoepitopes neoantigens immunotherapy nivolumab ipilimumab atezolizumab neoantigen cancer vaccine personalized neoantigen cancer vaccine ffpe pbmc stool immuno-oncology next generation sequencing (ngs)
improving care of osteoporosis: multi-modal intervention to increase testing and treatment (icommiitt)

Conditions: Osteoporosis

Summary: the purpose of this study is to rigorously test the incremental impact of simple, generalizable interventions to improve healthcare among older women at high risk for osteoporosis. building on the experience of our university of alabama at birmingham (uab) interdisciplinary team we have designed an innovative, scientifically rigorous, and highly feasible implementation research project in partnership with two kaiser permanente (kp) research centers. kaiser permanente, one of the nation's largest healthcare organizations, uses an integrated electronic medical record (emr), with full capture of pharmacy, clinical (including bmd results), and claims data, and cares for a racially/ethnically, socio-economically, and geographically diverse population. to address innovative questions in implementation research, we will perform a multi-modal group randomized trial involving over 18,000 patients seen by over 330 primary care providers (pcps) at 25 kp facilities in the northwest and southeast. if proven effective, our system-centered and patient-centered approach will advance the state of implementation science and be applicable to evidence implementation in other musculoskeletal disorders and to other health care settings.


Eligibility criteria:
inclusion criteria: * female * age 65 or older exclusion criteria: * prior osteoporosis testing (bmd) * prior osteoporosis treatment

Keywords: osteoporosis bmd bisphosphonates educational materials patient stories
influence of different anesthetic procedures on sleep disorder breathing

Conditions: Obstructive Sleep Apnea

Summary: obstructive sleep apnea (osa) is a common form of sleep disordered breathing characterized by partial or complete upper airway obstructions during sleep. osa is associated with major comorbidities and perioperative complications. these complications are caused not only by the osa itself, but also by exacerbations of this syndrome during the perioperative period (1). benzodiazepines, volatile anesthetics and opioids may lead to lower hypoxia and hypercapnia sensitivity and may cause respiratory depression (2-5). therefore, preference of neuraxial blockades and avoidance of opioids has been suggested for patients with osa (6). however, there is still lack of evidence to evaluate the effects of various anesthesia procedures on osa (6,7). we hypothesize different anesthetic procedures will have different effect on osa exacerbations in the postoperative period. accordingly, the aim of this study is to compare the number of sleep disordered breathing episodes in the postoperative period in patients with different anesthetic procedures.


Eligibility criteria:
inclusion criteria: * elective orthopedic surgery exclusion criteria: * already diagnosed sleep disorder breathing * continuous positive airway pressure therapy * tracheostomy * american society of anesthesiologists class iv-v

Keywords: anesthesia, obstructive sleep apnea
the effects of sleep deprivation on physiological and perceptual responses during exercise

Conditions: Sleep Deprivation

Summary: sleep deprivation has been found to impact exercise performance. the effects of both partial (several hours) and full (24+ hours) sleep deprivation on exercise performance has shown effects on rating of perceived exertion, rate of oxygen consumption, respiratory exchange ratio, and heart rate. a common practice with athletes is to perform regular physiological testing (submaximal and maximal) in order to assess their fitness and to determine training intensities. however, the effects of sleep deprivation on those same physiological test results has not been investigated therefore, the purpose of this study is to investigate the effects of partial sleep deprivation on physiological test results.


Eligibility criteria:
inclusion criteria: * injury-free, trained, male runners exclusion criteria: * female, untrained, injured
predictors of failed thrombolysis in acute myocardial infarction

Conditions: STEMI - ST Elevation Myocardial Infarction

Summary: the purpose of this observational study is to assess why thrombolytic treatment with tissue-plasminogen activator (t-pa) fails in patients with acute st-segment elevation myocardial infarction (stemi). the study will include 200 stemi patients at the time of arrival at oslo university hospital ullevål after receiving prehospital thrombolysis. a blood sample will be taken immediately for the study of factors related to coagulation, fibrinolysis and inflammation. levels of the biomarkers will be compared between patients with successful and failed thrombolysis.

this study aims to explore why thrombolytic treatment with tissue-plasminogen activator (t-pa) fails in up to 50 % of pasients with acute st-segment elevation myocardial infarction (stemi). this is important in norway due to the long geographic distances and the fact that up to 70 % of stemi patients in some norwegian areas receive thrombolysis in stead of primary, invasive revascularization with percutaneous coronary intervention (pci). today, no well-defined biomarker or score can predict the successfulness of thrombolytic therapy during stemi. as failed thrombolysis leads to larger myocardial infarctions and poorer outcome, defining factors for improved risk stratification is important. the trofami study is a prospective study which will include 200 stemi patients given prehospital thrombolysis. a blood sample will be taken immediately after hospital admission for the analysis of potential relevant biomarkers related to coagulation, fibrinolysis and inflammation. the biomarkers will be evaluated against the successfullness or not of thrombolysis. oslo university hospital is the largest stemi center in norway. each year, approximately 100 stemi patients given prehospital thrombolysis are hospitalized at ullevål. the inclusion is anticipated to take place during the time period 2022-2024.

Eligibility criteria:
inclusion criteria: stemi patients \> 18 years given prehospital thrombolysis. exclusion criteria: none.
fmt in inflammatory bowel disease

Conditions: Faecal Microbiota Transplantation; Crohn Disease; Ulcerative Colitis; Microscopic Colitis

Summary: this is a prospective observational cohort study, over 52 weeks, evaluating the the use of faecal microbiota transplantation amongst patients with inflammatory bowel disease and microscopic colitis


Eligibility criteria:
inclusion criteria: * patients with inflammatory bowel disease (crohn's disease or ulcerative colitis) or microscopic colitis proven on the basis of radiology, endoscopy or histology. * patients with clinically and endoscopically active, crohn's disease, ulcerative colitis or microscopic colitis * patient must have attempted reasonable medical therapies to control their disease without sufficient response. * all patients have to be capable of attending appointments, as well completing surveys and diagnostic tests for the duration of study follow up * the patient must be able to identify a likely stool donor exclusion criteria: * patients with an enteropathy or colitis which cannot definitively be diagnosed as ulcerative colitis, crohn's disease or microscopic colitis * patients with concurrent clostridium difficile infection * women who are pregnant or intending to become pregnant in the near future (less than 6 months). * neutrophils less than 1.0 x 109/l * albumin less than 20g/l * active gastrointestinal infection as identified by testing * a patient on steroids (prednisolone, budesonide) at a dose that cannot be safely tapered to zero within 6 weeks of initial fmt, due to the risk of adrenal insufficiency * short gut syndrome and/or small intestine less than 1.5m in length as measured intra-operatively * perforation or active internal fistulising disease or enterocutaneous fistulae. * any patient that the clinicians feel is incapable of participating in the safe use of fmt. * current use of antibiotics for any condition
a phase 1 trial of erx-315 in participants with advanced solid tumors

Conditions: Advanced Solid Tumor; Metastatic Breast Cancer; Metastatic Ovarian Cancer; Metastatic Endometrial Cancer; Metastatic Liver Cancer; Metastatic Pancreatic Cancer

Summary: this is a phase 1 study to assess the safety of erx-315 in patients with advanced solid tumors that have failed approved systemic therapies.

the goal of this open-label, dose escalation and cohort expansion phase 1 clinical trial is to determine the safety, tolerability and pharmacokinetics of erx-315 in patients with advanced solid tumors, who have progressed on prior approved systemic therapies. participants will receive erx-315 as an intravenous (iv) injection twice a week, over 21-day cycles.

Eligibility criteria:
inclusion criteria: * patients must be at least 18 years of age at the time of signing the informed consent. * eastern cooperative oncology group (ecog) performance status 0 or 1. * patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective * patients must have measurable disease as per response evaluation criteria in solid tumors (recist) v1.1. * adequate baseline organ function and hematologic function * life expectancy \>3 months exclusion criteria: * systemic anti cancer therapy within 4 weeks of first dose of study drug * major surgery (as defined by the investigator) within 4 weeks of first dose of study drug. * uncontrolled intercurrent illnesses * known history of lipa deficiency, such as wolman disease or cholesterol ester storage disease.
evaluation of predictive visual analog scale (vas) for determining the ingesta of patients carrying a digestive cancer

Conditions: Digestive System Neoplasms

Summary: the main objective of our study is to determine if the evaluation of ingesta of cancer patients by vas (on the day of hospitalization) is able to predict the actual ingesta of patients during hospitalization (for patients malnourished, at risk of malnutrition or risk free).


Eligibility criteria:
inclusion criteria: * patients aged over 18 years * admitted to hospital for systemic therapy of gastrointestinal cancer * signature of the non-opposition. exclusion criteria: * patients who because of their affection will fasted more than 12:00 during the three days preceding hospitalization. * artificial nutrition patients
turkish version of mini osteoarthritis knee and hip quality of life questionnaire

Conditions: Knee Osteoarthritis; Hip Osteoarthritis

Summary: in this paper, the adaptation of the mini-oakhqol questionnaire in the turkish population analyzing the feasibility, reliability, and validity of the questionnaire was documented.

knee and hip osteoarthritis are common diseases that play an important role in health-related quality of life (hr-qol). assessing hr-qol with a disease- and site-specific hr-qol is more advantageous than generic scales. in that concept, to our knowledge, there is not any osteoarthritis- and lower limb-specific hr-qol instrument to use in turkey. mini-oakhqol was derived from the oakhqol questionnaire, which was developed to assess the quality of life (qol) in subjects with lower limb osteoarthritis. its good psychometric properties have recently been shown and validation studies have been done in several populations. mini-oakhqol's validation study has not been done before in turkey. the aim is to investigate the validity and reliability of the turkish version of the mini-oakhqol. patients diagnosed with knee or hip osteoarthritis were recruited. for cross-cultural adaptation, items of mini-oakhqol were selected from the interrelated turkish version of the oakhqol study in which the adaptation process had already done. missing data, floor effect, and ceiling effect were calculated. reliability analysis with internal consistency and test-retest reliability were discovered. face, content, convergent, and divergent validities were applied.

Eligibility criteria:
inclusion criteria: * symptomatic knee or hip oa * between 18-75 years exclusion criteria: * history of inflammatory disease, * a disease involving cognitive deficit and psychiatric illness, * knee or hip surgery within one year, * another disease of the lower limbs
effects of stereotype threat on impulsivity and its relation to alcohol use in african americans: an fmri study

Conditions: Alcohol Drinking

Summary: the purpose of this study is to investigate the behavioral and neural correlates of stress exposure. results from this study will enrich the understanding of how sociocultural, behavioral, and neural factors combine to influence alcohol use.


Eligibility criteria:
inclusion criteria: * between 21 and 35 years of age (inclusive); * fluent in english; * right-handed exclusion criteria: * younger than 21 years of age; * left-handed
tempus aries: a biobank registry platform study in oncology

Conditions: Cancer

Summary: this study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctdna biomarker profiling at specific time points in addition to standard of care therapy.


Eligibility criteria:
inclusion criteria: 1. ≥18 years of age 2. willing to participate in the research 3. able to provide informed consent 4. must be diagnosed with cancer exclusion criteria: 1. not willing or able to have additional blood samples collected

Keywords: ctdna next-generation sequencing oncology
precise antiplatelet therapy guided by platelet aggregation function in acute ischemic stroke（path-stroke）

Conditions: Ischemic Stroke; Antiplatelet Drug

Summary: 1. main objective: to explore the efficacy of precise antiplatelet therapy guided by platelet aggregation function in reducing the incidence of 30 day platelet hyperresponsiveness in patients with non-cardiogenic ischemic stroke. 2. secondary objective: to explore the efficacy and safety of antiplatelet therapy in patients with non-cardiogenic ischemic stroke under the guidance of platelet aggregation function.

non cardiac cerebral infarction accounts for more than 50% of cerebral infarction cases, and the key to its onset is increased platelet aggregation function. aspirin and clopidogrel are class a recommended drugs for the prevention and treatment of non cardiac cerebral infarction. however, after regular use of aspirin and clopidogrel, more than 30% of stroke patients still experience high on treatment platelet reactivity (hopr) due to aspirin resistance and clopidogrel resistance, leading to stroke recurrence. antiplatelet therapy is the cornerstone of the prevention and treatment of non cardiogenic cerebral infarction. therefore, clinical research on the prevention and treatment of hopr with antiplatelet therapy for non cardiogenic cerebral infarction is of great significance, which can help partially solve the bottleneck of resistance to antiplatelet therapy in cerebral infarction.platelet aggregation function testing can timely detect antiplatelet therapy hopr, guide drug adjustment, and is expected to become a testing standard for the prevention and treatment of antiplatelet therapy resistance.

Eligibility criteria:
inclusion criteria: 1. aged from 18 to 80 years; 2. diagnosed with non-cardiogenic ischemic stroke according to who criteria, confirmed by cranial ct or mri to exclude hemorrhagic stroke.; 3. first stroke onset ≥ 1 month and ≤ 3 months; 4. mrs score \<=2 points; 5. undergoing antiplatelet therapy with 100mg aspirin daily for at least 8 days; 6. informed consent signed by the patient or their family member. exclusion criteria: 1. history of recurrent stroke. 2. history of gastrointestinal bleeding, intracranial hemorrhage, or other bleeding disorders. 3. contraindications or intolerance to antiplatelet therapy medications. 4. severe cardiac, pulmonary, hepatic, or renal insufficiency, or presence of severe comorbid conditions (e.g., end-stage malignant tumors, severe single/multiple organ failure). 5. poor compliance, inability to cooperate with study requirements.
studying a tumor marker for testicular cancer, skin cancer, small intestine cancer, and pancreatic cancer

Conditions: Non-melanomatous Skin Cancer; Pancreatic Cancer; Small Intestine Cancer; Testicular Germ Cell Tumor

Summary: rationale: studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is evaluating a tumor marker for testicular cancer, skin cancer, small intestine cancer, and pancreatic cancer.

objectives: * to identify tab3 transcript/protein as a molecular marker of cancer, specifically testicular, skin, small intestine, and pancreatic cancer. * to characterize tab3 and its signaling networks that are involved in tumorigenesis. outline: tumor tissue samples from paraffin-embedded tissue blocks are analyzed for tab3 transcript and protein expression using in situ hybridization and immunostaining with tab3 crna probe and antibody. antibodies against the proteins involved in the nfkb signaling pathway (e.g., p65, tak1, myd88, and akt) are used in the immunostaining assays.

Eligibility criteria:
disease characteristics: * paraffin tissue blocks from surgical pathology cancer cases, specifically testicular, skin, small intestine, and pancreatic cancer, available patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: skin cancer small intestine cancer pancreatic cancer malignant testicular germ cell tumor testicular teratoma
transversus abdominis plane block in acute appendicitis pain managment

Conditions: Acute Appendicitis; Acute Abdomen; Postoperative Pain

Summary: in this study, it was aimed to investigate the analgesic efficacy of the preoperatively applied transversus abdominis plane (tap) block in the management of acute appendicitis-related abdominal pain and post-appendectomy pain.

tap block creates an analgesic effect by blocking both sensory skin dermotams and viscerosomatic transmission. tap block with ultrasound was first performed by hebbard, and the use of usg made the procedure faster and safer. tap block has been successfully applied for analgesia in procedures such as laparoscopic colocystectomy, inguinal hernia repair, abdominal hysterectomy, prostatectomy and appendectomy. according to the surgical incision to be applied, tap block is performed from different anatomical regions. it is also applied for pain palliation in intra-abdominal etiologies or rarely for anesthesia in surgical procedures. the analgesic efficacy of tap block on preoperative abdominal pain and postoperative surgical pain in acute appendicitis was investigated.

Eligibility criteria:
inclusion criteria: * patients over the age of 18 with a diagnosis of acute appendicitis, * with abdominal pain, * tap block applied for perioperative pain management. exclusion criteria: * the data of patients who underwent laparoscopic appendectomy * additional surgical procedure other than appendectomy (right hemicolectomy, etc.) * who were diagnosed other than acute appendicitis after the surgical procedure (diverticulitis, tumor, etc.),

Keywords: transversus abdominis plane nerve block acute appendicitis acute pain postoperative pain